Press Releases

Press Releases

  • Weill Cornell Medicine Creates a Renewable Supply of Blood Stem Cells That Hold the Promise of Treatment and Potential Cures for Multiple Disorders

    Technology Offers New Approach to Regenerating the Blood and Immune System
    May 17, 2017

    SAN DIEGO, CA –A team of researchers at Weill Cornell Medicine have discovered an innovative method to make an unlimited supply of healthy blood and immune cells from the readily available cells that line blood vessels. The work published in Nature today is the culmination of efforts by a team of researchers led by Professor Shahin Rafii MD, director of the Ansary Stem Cell Institute, chief of the Division of Regenerative Medicine and the scientific founder of Angiocrine Bioscience.

    Stem cells that produce cells that comprise the blood and immune system (hematopoietic stem cells) are not only critical to human vitality and health but also can be used therapeutically to treat and even cure various diseases from cancer to devastating genetic diseases, such as sickle cell anemia and primary immune deficiency (a.k.a. bubble baby syndrome). Ample, high-quality generation of hematopoietic stem cells has been a ‘holy grail’ of modern medical science.

    As described in the publication, the team at Weill Cornell Medicine have discovered a novel system for reprogramming endothelial cells into hematopoeitic stem cells that can regenerate the blood cells and the immune system. Endothelial cells line the blood vessels throughout the body and are easily obtainable. Two distinct methodologies are used to accomplish this feat: a) reprogramming of endothelial cells with four genes that encode proteins into hematopoeitic stem cells; and, b) utilizing another specialized type of endothelial cell (E-CELTM) that enables clinical and commercial scale production of blood and immune system forming stem cells. Both technologies were invented by Professor Rafii and his team, and exclusively licensed by Angiocrine Bioscience, Inc.

    “The potential clinical applications of this new powerful technology is vast,” commented Paul Finnegan MD, Chief Executive Officer of Angiocrine Bioscience. “Just imagine the possibilities generated by a process that can produce your own stem cells, for example skin, so you can treat or even cure yourself. We applaud the groundbreaking work that Professor Rafii and his team continues to produce at Weill Cornell Medical, to bring the future of regenerative medicine within our reach, near-term.”

    About Angiocrine Bioscience Inc.
    Angiocrine Bioscience is a privately held San Diego based biopharmaceutical company and a world-leader in regenerative engineered endothelial cells. Angiocrine’s proprietary E-CEL™ cells simulate the vascular stem cell niche, special locations within vital organs where certain endothelial cells work with the organ’s stem cells to start the regenerative and repair process in our body. The Ψ Psi-CEL™ technology enables the production of blood and immune system forming (hematopoietic) stem cells from endothelial cells. Together, they represent a potentially transformative new approach to treatment and cure of various diseases. Angiocrine’s approach is unique and based on over twenty years of research in vascular and regenerative biology by its scientific founder, Professor Shahin Rafii MD of Weill Cornell Medical.

    For additional information, please contact:

    Angiocrine Bioscience, Inc.
    John R. Jaskowiak
    (408) 646-2265
    jjaskowiak@angiocrinebio.com

  • Angiocrine Bioscience Announces Collaboration for Clinical Cell Manufacturing Platform with Terumo BCT

    Improved Scalability for E-CEL™ Manufacturing with Quantum® Cell Expansion System
    January 11, 2016

    SAN DIEGO, CA—(Business Wire) Angiocrine Bioscience Inc. today announced a three-year collaboration agreement with Terumo BCT Inc., a global leader in blood component, therapeutic apheresis and cellular technologies, to implement Terumo BCT’s Quantum Cell Expansion System as a manufacturing platform for its E-CEL™ technology and therapeutic candidates. The Quantum system, a state-of-the-art, functionally closed hollow-fiber bioreactor technology, streamlines the cell culture process and furthers the research and development of Angiocrine’s cell therapy products by enhancing process scalability, increasing reproducibility and reducing costs. “As we advanced our discovery and pre-clinical therapeutic programs, it was critical to identify a key collaborator that would help us streamline our processes and enable manufacturing scale up in a predictable and effective manner. The early adoption of an automated cell expansion platform, the Quantum system, in our research and development activities will accelerate our pace as we work to rapidly advance our therapeutic candidates into the clinic, and we are keen to work with Terumo BCT to leverage their expertise in cell culture automation and scale up,” commented Paul Finnegan, MD, Angiocrine’s CEO.

    Cell culture processes can be optimized and configured on the Quantum system manufacturing platform to expand several cell types, including some used in ongoing clinical trials in Europe. Angiocrine believes this helps develop various potential therapeutic indications being addressed by Angiocrine’s E-CEL technology. The combination of protocol flexibility and process control through automation provides a significant advantage over manual flask-based methods and positions the Quantum system ideal for a range of production scenarios from bench top research to commercial manufacturing. “Angiocrine Bioscience has a novel approach to regenerative medicine with its E-CEL technology and we are excited about working with them to achieve clinical scale production”, added Dave Flaten, Vice President, Cell Processing, Terumo BCT.

    About Angiocrine Bioscience Inc.
    Angiocrine Bioscience is a world-leader in genetically-modified endothelial cell-based technology (the E-CEL™ Technology) which has multiple applications in regenerative medicine. Angiocrine’s approach is unique and based on over twenty years of research in vascular and regenerative biology. We aim to transform the standards of medical practice through our rationally designed, inspired by nature, therapeutic platforms designed to drive resident stem cell renewal in a variety of disease settings. Angiocrine’s core technology is licensed from Weill Cornell Medical College and was invented and developed by Professor Shahin Rafii, MD. His work related to Angiocrine technology has been published in numerous peer-reviewed journals, including Nature, Cell and Blood.

    About Terumo BCT
    Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

    For additional information, please contact:

    Angiocrine Bioscience, Inc.
    John R. Jaskowiak
    (408) 646-2265
    jjaskowiak@angiocrinebio.com

  • Angiocrine Bioscience Licenses New Stem Cell Technology From Weill Cornell Medical College

    Technology Offers Safer Approach to Stem Cell Transplantation
    August 21, 2014

    NEW YORK, NY – (Business Wire) Angiocrine Bioscience, Inc. announced today that it has licensed the rights to a new technology developed by a team of researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College. The team was led by Dr. Shahin Rafii, director of the Ansary Stem Cell Institute, professor of medicine, genetic medicine and reproductive medicine, and a founder of Angiocrine Bioscience. This scientific advance, reported in the July 2 issue of Nature, could potentially lead to therapies for patients with blood disorders from their own cells.

    This technology provides a means of converting a patient’s own vascular cells, known as endothelial cells, directly into blood stem cells. The endothelial cells are acquired from a biopsied piece of skin and are then “educated” on a bed of VeraVecTM cells (proprietary to Angiocrine Bioscience) to form multipotent blood cells that are capable of producing red cells that carry oxygen, white cells that provide immunity, and platelets to prevent bleeding. This approach could potentially provide an abundant and safe source of new blood stem cells capable of treating a variety of diseases without the risk of graft versus host disease, a serious, life-threatening complication often associated with stem cell transplants derived from a donor.

    “We hope that our method will offer the first safe technology to treat a wide spectrum of serious disorders. The VeraVecTM cells form a nurturing niche for the survival and growth of the reprogrammed blood cells, similar to what happens developmentally during blood production. A particularly important aspect of this study was that the reprogrammed cells engrafted in the bone marrow when implanted into rodents and morphed into the various types of blood cells,” said Dr. Rafii.

    “This technology nicely complements our efforts in applying our VeraVecTM platform to the expansion of umbilical cord blood stem cells, another approach toward making stem cell transplant safer and more broadly available to patients in need, ” added Geoff Davis, Angiocrine’s CEO.

    About Angioicrine Bioscience, Inc.

    Angiocrine Bioscience is a privately held biotech company focused on applying vascular biology to new therapeutic applications. Angiocrine’s VeraVecTM technology platform is based on endothelial cells that have been genetically modified such that they can be rapidly and durably expanded in culture. Because these cells secrete and display factors essential for stem cell growth and proliferation, they can be used to support cell-based therapies, stem cell transplant, and regenerative medicine applications. VeraVecTM products are currently marketed for research-use only purposes to academic laboratories, medical research institutes, and pharmaceutical and biotechnology companies.

    For additional information, please contact:

    Angiocrine Bioscience, Inc.
    John R. Jaskowiak
    (302) 475-8645
    jjaskowiak@angiocrinebio.com